Roles of PET/CT in Predicting the Prognosis of Diffuse Large B Cell Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy.
10.19746/j.cnki.issn.1009-2137.2020.04.018
- Author:
Xin-Qi ZHENG
1
;
Chong-Yang DING
2
;
Yi-Xin ZOU
3
;
Hua-Yuan ZHU
1
;
Li WANG
3
;
Lei FAN
3
;
Wei XU
3
;
Jian-Yong LI
4
,
5
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu Province, China;Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China,Pukou CLL Center, Pukou Division of Jiangsu Provincial Hospital, Nanjing 210031, Jiangsu Province, China.
2. Department of Nuclear Medicine, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu Province, China.
3. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu Province, China;Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
4. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, Jiangsu Province, China;Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China,Pukou CLL Center, Pukou Division of Jiangsu Provincial Hospital, Nanjing 210031, Jiangsu Province, China,E-mail: lijianyonglm@
5. com.
- Publication Type:Journal Article
- MeSH:
Cell- and Tissue-Based Therapy;
Fluorodeoxyglucose F18;
Humans;
Lymphoma, Large B-Cell, Diffuse;
Positron Emission Tomography Computed Tomography;
Positron-Emission Tomography;
Prognosis;
Receptors, Chimeric Antigen;
Retrospective Studies
- From:
Journal of Experimental Hematology
2020;28(4):1189-1196
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the prognosis prediction value of PET/CT in DLBCL patients treated with CAR-T therapy.
METHODS:The effects of PET/CT were retrospectively explored on 13 R/R DLBCL patients who were treated with CAR-T therapy. Parameters reflecting tumor metabolic burden, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were measured before and after CAR-T treatment.
RESULTS:Patients with larger baseline MTV or longer sum of longest diameters showed shorter overall survival (OS) time than those with low tumor burden. Patients achieved complete remission (CR), partial remission (PR) and minor remission (MR) determined by response evaluation criteria in lymphoma (RECIL) in 12 weeks showed progression-free survival and OS time superior to those of patients with no remission. In addition, it was found that 2 patients with residual masses classified as PR by contrast-enhanced CT of patients were evaluated as complete metabolic response by PET/CT imaging.
CONCLUSION:PET/CT shows a great value in the evaluation of prognosis and response in CAR-T-treated R/R DLBCL patients.
